Literature DB >> 26222560

Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.

Sudheer Kumar Gara1, Li Jia, Maria J Merino, Sunita K Agarwal, Lisa Zhang, Maggie Cam, Dhaval Patel, Electron Kebebew.   

Abstract

Familial nonmedullary thyroid cancer accounts for 3 to 9% of all cases of thyroid cancer, but the susceptibility genes are not known. Here, we report a germline variant of HABP2 in seven affected members of a kindred with familial nonmedullary thyroid cancer and in 4.7% of 423 patients with thyroid cancer. This variant was associated with increased HABP2 protein expression in tumor samples from affected family members, as compared with normal adjacent thyroid tissue and samples from sporadic cancers. Functional studies showed that HABP2 has a tumor-suppressive effect, whereas the G534E variant results in loss of function.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26222560      PMCID: PMC4562406          DOI: 10.1056/NEJMoa1502449

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

1.  The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis.

Authors:  Rick van Minkelen; Marieke C H de Visser; Hans L Vos; Rogier M Bertina; Frits R Rosendaal
Journal:  Blood       Date:  2005-06-15       Impact factor: 22.113

2.  Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism.

Authors:  Franca Franchi; Ida Martinelli; Eugenia Biguzzi; Paolo Bucciarelli; Pier Mannuccio Mannucci
Journal:  Blood       Date:  2006-02-15       Impact factor: 22.113

3.  Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).

Authors:  Joana S Pereira; Joana Gomes da Silva; Rute Alexandra Tomaz; António Evaristo Pinto; Maria João Bugalho; Valeriano Leite; Branca Maria Cavaco
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

4.  A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.

Authors:  Elly S W Ngan; Brian H H Lang; Tingting Liu; Cathy K Y Shum; Man-Ting So; Danny K C Lau; Thomas Y Y Leon; Stacey S Cherny; Sophia Y Tsai; Chung-Yau Lo; Ui-Soon Khoo; Paul K H Tam; Maria-Mercè Garcia-Barceló
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

5.  Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism.

Authors:  Berthold Hoppe; Farzaneh Tolou; Hartmut Radtke; Holger Kiesewetter; Thomas Dörner; Abdulgabar Salama
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

6.  Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator.

Authors:  N H Choi-Miura; T Tobe; J Sumiya; Y Nakano; Y Sano; T Mazda; M Tomita
Journal:  J Biochem       Date:  1996-06       Impact factor: 3.387

7.  Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells.

Authors:  K T Schmeidler-Sapiro; O D Ratnoff; E M Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

8.  Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.

Authors:  Amy Willis; Eun Joo Jung; Therese Wakefield; Xinbin Chen
Journal:  Oncogene       Date:  2004-03-25       Impact factor: 9.867

9.  Factor VII-activating protease in patients with acute deep venous thrombosis.

Authors:  Johannes J Sidelmann; Frank Vitzthum; Eva Funding; Anna-Marie B Münster; Jørgen Gram; Jørgen Jespersen
Journal:  Thromb Res       Date:  2008-04-18       Impact factor: 3.944

10.  The hepatocyte growth factor regulatory factors in human breast cancer.

Authors:  Christian Parr; Gareth Watkins; Robert E Mansel; Wen G Jiang
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

View more
  49 in total

Review 1.  Thyroid cancer in 2015: Molecular landscape of thyroid cancer continues to be deciphered.

Authors:  Yuri E Nikiforov
Journal:  Nat Rev Endocrinol       Date:  2015-12-15       Impact factor: 43.330

Review 2.  Evolving molecularly targeted therapies for advanced-stage thyroid cancers.

Authors:  Keith C Bible; Mabel Ryder
Journal:  Nat Rev Clin Oncol       Date:  2016-03-01       Impact factor: 66.675

3.  Response.

Authors:  Tao Zhang; Xiaopei Shen; Mingzhao Xing
Journal:  J Natl Cancer Inst       Date:  2016-05-06       Impact factor: 13.506

4.  RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.

Authors:  Luis G Carvajal-Carmona; Ian Tomlinson; Ruta Sahasrabudhe
Journal:  J Natl Cancer Inst       Date:  2016-05-06       Impact factor: 13.506

5.  RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.

Authors:  Pasquale Simeone; Saverio Alberti
Journal:  J Natl Cancer Inst       Date:  2016-07-14       Impact factor: 13.506

6.  G534E Variant in HABP2 and Nonmedullary Thyroid Cancer.

Authors:  Macarena Ruiz-Ferrer; Raquel M Fernández; Elena Navarro; Guillermo Antiñolo; Salud Borrego
Journal:  Thyroid       Date:  2016-07       Impact factor: 6.568

Review 7.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

Review 8.  The impact of family history on non-medullary thyroid cancer.

Authors:  I J Nixon; C Suárez; R Simo; A Sanabria; P Angelos; A Rinaldo; J P Rodrigo; L P Kowalski; D M Hartl; M L Hinni; J P Shah; A Ferlito
Journal:  Eur J Surg Oncol       Date:  2016-08-11       Impact factor: 4.424

Review 9.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

10.  Transforming Growth Factor-β (TGF-β) Inhibits the Expression of Factor VII-activating Protease (FSAP) in Hepatocytes.

Authors:  Silke Leiting; Sebastian Seidl; Adoracion Martinez-Palacian; Lars Muhl; Sandip M Kanse
Journal:  J Biol Chem       Date:  2016-07-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.